| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 4.6 | 3.0 | 6.7 |
| Total income | 295.0 | 379.0 | 399.0 |
| Exceptional items | -7.1 | 0.0 | -100.0 |
| Net profit | -88.7 | 10.5 | -68.8 |
| Operating margin | -31.5% | 1.5% | -16.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: ONESOURCE. Figures extracted from the filing.
OneSource Specialty Pharma Ltd: key numbers
- Share price
- ₹1,552.50
- Market cap
- ₹17,803 Cr
- Revenue (annual)
- ₹1,422 Cr
- Net profit (annual)
- ₹-73.80 Cr
- P/E (TTM)
- -366.2×Sector 49.8×
- Promoter holding
- 30.48%+0.00% QoQ
- FII holding
- 19.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from OneSource Specialty Pharma Ltd
All →OneSource Specialty Pharma Employee Stock Options
Onesource Specialty Pharma Limited has allotted 900 equity shares under its Employee Stock Option Plan. This allotment updates the company's total paid-up share capital.
OneSource Specialty Pharma Employee Stock Options
OneSource Specialty Pharma allotted 900 shares under its ESOP 2021 scheme at an exercise price of ₹278 per share, totaling ₹0.03 Crore.
- Value
- ₹0.03 Cr
OneSource Specialty Pharma Management Change
Onesource Specialty Pharma Limited appointed B S R & Co LLP as its Statutory Auditor for a 60-month term, effective September 23, 2026.
OneSource Specialty Pharma Other Announcement
OneSource Specialty Pharma Ltd appointed M/s B S R & Co LLP as its Statutory Auditors for a five-year term ending at the 24th AGM.
OneSource Specialty Pharma Annual General Meeting
OneSource Specialty Pharma held its 19th Annual General Meeting on September 23, 2026. Shareholders transacted ordinary and special business items, including re-appointments and related party approvals.
OneSource Specialty Pharma Annual General Meeting
OneSource Specialty Pharma issued an addendum to its 19th AGM notice regarding additional disclosures for agenda items about material related party transactions.